Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioRestorative Therapies, Inc. stock logo
BRTXQ
BioRestorative Therapies
$1.72
+1.2%
$1.71
$0.00
$0.06
$2.82B102.3662.17 million shs7,225 shs
Guardant Health, Inc. stock logo
GH
Guardant Health
$47.23
-4.6%
$43.48
$17.85
$50.89
$5.83B1.452.16 million shs3.56 million shs
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$33.06
-5.7%
$32.49
$11.20
$72.98
$7.34B1.6516.46 million shs38.75 million shs
Option Care Health, Inc. stock logo
OPCH
Option Care Health
$32.31
+5.3%
$33.34
$21.39
$35.53
$5.31B1.071.81 million shs4.19 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioRestorative Therapies, Inc. stock logo
BRTXQ
BioRestorative Therapies
+1.18%-0.58%-4.97%-26.81%+38.71%
Guardant Health, Inc. stock logo
GH
Guardant Health
-4.64%+3.28%+10.87%-5.43%+162.39%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-5.76%+23.59%+11.22%-2.43%+164.06%
Option Care Health, Inc. stock logo
OPCH
Option Care Health
+5.28%+0.52%-7.55%+2.90%+8.10%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioRestorative Therapies, Inc. stock logo
BRTXQ
BioRestorative Therapies
N/AN/AN/AN/AN/AN/AN/AN/A
Guardant Health, Inc. stock logo
GH
Guardant Health
3.9513 of 5 stars
2.54.00.04.32.72.50.6
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
3.1857 of 5 stars
3.02.00.00.03.23.31.9
Option Care Health, Inc. stock logo
OPCH
Option Care Health
3.1503 of 5 stars
1.43.00.04.23.12.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioRestorative Therapies, Inc. stock logo
BRTXQ
BioRestorative Therapies
0.00
N/AN/AN/A
Guardant Health, Inc. stock logo
GH
Guardant Health
3.05
Buy$49.003.75% Upside
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.08
Hold$36.9211.67% Upside
Option Care Health, Inc. stock logo
OPCH
Option Care Health
2.88
Moderate Buy$35.509.87% Upside

Current Analyst Ratings Breakdown

Latest BRTXQ, HIMS, GH, and OPCH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/30/2025
Option Care Health, Inc. stock logo
OPCH
Option Care Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$38.00 ➝ $38.00
4/30/2025
Option Care Health, Inc. stock logo
OPCH
Option Care Health
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$38.00 ➝ $40.00
4/29/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderperform ➝ Underperform$22.00 ➝ $26.00
4/29/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$60.00 ➝ $40.00
4/29/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$44.00 ➝ $30.00
4/25/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$27.00 ➝ $25.00
4/22/2025
Option Care Health, Inc. stock logo
OPCH
Option Care Health
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$36.00 ➝ $36.00
4/21/2025
Option Care Health, Inc. stock logo
OPCH
Option Care Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$38.00 ➝ $38.00
4/10/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$60.00 ➝ $55.00
4/10/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$55.00
4/10/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$39.00 ➝ $33.00
(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioRestorative Therapies, Inc. stock logo
BRTXQ
BioRestorative Therapies
$110K25,637.79N/AN/A($0.68) per share-2.53
Guardant Health, Inc. stock logo
GH
Guardant Health
$739.02M7.89N/AN/A$1.34 per share35.25
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$1.48B4.97N/AN/A$1.61 per share20.53
Option Care Health, Inc. stock logo
OPCH
Option Care Health
$5.00B1.06$1.88 per share17.19$8.03 per share4.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioRestorative Therapies, Inc. stock logo
BRTXQ
BioRestorative Therapies
-$12.52M-$1.07N/AN/AN/AN/AN/AN/A
Guardant Health, Inc. stock logo
GH
Guardant Health
-$479.45M-$3.56N/AN/AN/A-59.05%-19,157.20%-25.96%N/A
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-$23.55M$0.5475.1463.58N/A8.19%10.97%8.29%5/5/2025 (Estimated)
Option Care Health, Inc. stock logo
OPCH
Option Care Health
$267.09M$1.2227.1525.642.304.37%15.30%6.57%N/A

Latest BRTXQ, HIMS, GH, and OPCH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2025Q1 2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.11N/AN/AN/A$535.21 millionN/A
4/29/2025Q1 2025
Option Care Health, Inc. stock logo
OPCH
Option Care Health
$0.36$0.40+$0.04$0.28$1.26 billion$1.33 billion
2/24/2025Q4 2024
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.09$0.11+$0.02$0.11$494.56 million$481.14 million
2/20/2025Q4 2024
Guardant Health, Inc. stock logo
GH
Guardant Health
-$0.75-$0.90-$0.15-$0.90$192.50 million$201.81 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioRestorative Therapies, Inc. stock logo
BRTXQ
BioRestorative Therapies
N/AN/AN/AN/AN/A
Guardant Health, Inc. stock logo
GH
Guardant Health
N/AN/AN/AN/AN/A
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/AN/AN/AN/AN/A
Option Care Health, Inc. stock logo
OPCH
Option Care Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioRestorative Therapies, Inc. stock logo
BRTXQ
BioRestorative Therapies
N/AN/AN/A
Guardant Health, Inc. stock logo
GH
Guardant Health
N/A
6.22
5.85
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/A
2.14
1.82
Option Care Health, Inc. stock logo
OPCH
Option Care Health
0.77
1.73
1.32

Institutional Ownership

CompanyInstitutional Ownership
BioRestorative Therapies, Inc. stock logo
BRTXQ
BioRestorative Therapies
N/A
Guardant Health, Inc. stock logo
GH
Guardant Health
92.60%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
63.52%
Option Care Health, Inc. stock logo
OPCH
Option Care Health
98.05%

Insider Ownership

CompanyInsider Ownership
BioRestorative Therapies, Inc. stock logo
BRTXQ
BioRestorative Therapies
12.20%
Guardant Health, Inc. stock logo
GH
Guardant Health
5.50%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
17.71%
Option Care Health, Inc. stock logo
OPCH
Option Care Health
0.64%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioRestorative Therapies, Inc. stock logo
BRTXQ
BioRestorative Therapies
71.64 billionN/ANot Optionable
Guardant Health, Inc. stock logo
GH
Guardant Health
1,790123.42 million116.76 millionNot Optionable
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
650222.17 million179.79 millionOptionable
Option Care Health, Inc. stock logo
OPCH
Option Care Health
5,600164.24 million169.09 millionOptionable

Recent News About These Companies

Why Option Care Health, Inc. (OPCH) Went Down On Tuesday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BioRestorative Therapies stock logo

BioRestorative Therapies OTCMKTS:BRTXQ

$1.72 +0.02 (+1.18%)
As of 04/29/2025

BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company's two core programs are related to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow, and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc and treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The company have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100to treat persistent lower back pain due to painful degenerative discs. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy in preclinical stage to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). In addition, the company provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York. On March 20, 2020, BioRestorative Therapies, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of New York.

Guardant Health stock logo

Guardant Health NASDAQ:GH

$47.23 -2.30 (-4.64%)
As of 04/30/2025 04:00 PM Eastern

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Hims & Hers Health stock logo

Hims & Hers Health NYSE:HIMS

$33.06 -1.98 (-5.65%)
As of 04/30/2025 03:59 PM Eastern

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Option Care Health stock logo

Option Care Health NASDAQ:OPCH

$32.31 +1.62 (+5.28%)
As of 04/30/2025 04:00 PM Eastern

Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.